Dietrich Wenderoth

Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial

David M. Reid, Rodney Hughes, Roland Laan et al. · Journal of Bone and Mineral Research · 2000 · 590 citations · Full text

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey.

O. H. Sørensen, G. Crawford, Hindrik Mulder et al. · Bone · 2003 · 254 citations

Long-term Efficacy, Clinical Therapeutic, Gamble Pharmaceuticals +7

Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study

Steven Boonen, Eric Orwoll, Dietrich Wenderoth et al. · Journal of Bone and Mineral Research · 2008 · 188 citations

Bone Disease, Bone Turnover Markers, Bone Health +11

Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover

Richard Eastell, R.A. Hannon, Dietrich Wenderoth et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 87 citations · Full text

Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial

Michael Hooper, Peter R. Ebeling, Adam P. Roberts et al. · Climacteric · 2005 · 55 citations